Skip to content
Screener

Roivant Sciences ROIV Q1 2026 earnings

Reported August 6, 2026 · Before market open

Revenue$1.4MMiss by $614.8K
EPS-$0.33Miss by $0.03
Revenue estimate$2.1M
EPS estimate-$0.30
“This quarter has been a moment of relative quiet between our incredibly busy last twelve months and our even busier year ahead. Our teams are deep in preparation for the potential launch of brepocitinib in dermatomyositis, we have enrolled the first patients in a new Phase 3 trial in cutaneous sarcoidosis, and we expect topline readouts from our NIU, PH-ILD and CLE studies before year end. We remain focused on delivering for patients across each of these programs, and if we are successful across even some of these endeavors, we will look radically different on the other side.”
Matt Gline

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$3.4M
EPS estimate-$0.41

Financials

Q1 2026

Income statement

See full
Revenue$1.4M-33.5%
Operating income-$366.0M-28.5%
Net income-$189.8M+15.0%
EPS (diluted)-$0.26+21.2%

Balance sheet

See full
Cash & equivalents$77.1M-18.7%
Total debt$107.2M+7.5%
Total equity$4.2B-2.6%
Total assets$5.3B+5.4%

Cash flow

See full
Operating cash flow-$270.5M-32.4%
CapEx$419.0K-89.6%
Free cash flow-$270.9M-30.0%

Valuation & ratios

Valuation

as of 08/27/26
See full
Market cap$26.55B+224%
Enterprise value$26.58B+224%
P/S3,524.4×+3,172×

Profitability

See full
FCF margin-10,901%-22,382pp

Returns & leverage

See full
Debt / equity0×0.0×
Current ratio16.7×-23.8×

Segments

By segment

See full
Reportable Segment$1.4M-33.5%

FAQ

When did Roivant Sciences report Q1 2026 earnings?
Roivant Sciences (ROIV) reported Q1 2026 earnings on August 6, 2026 before market open.
What were Roivant Sciences's Q1 2026 revenue and EPS?
Roivant Sciences reported revenue of $1.4M and eps of $-0.33 for Q1 2026.
Did Roivant Sciences beat estimates in Q1 2026?
Revenue missed the consensus estimate of $2.1M by $614.8K. EPS missed the consensus estimate of $-0.30 by $0.03.
Where can I find Roivant Sciences's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001635088-26-000088) and the 10-Q periodic report (0001635088-26-000090) directly on SEC EDGAR. The filing index links above go to sec.gov.